UBS Initiates Coverage On Insmed with Buy Rating, Announces Price Target of $46
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Trung Huynh initiates coverage on Insmed (NASDAQ:INSM) with a Buy rating and a price target of $46.
February 27, 2024 | 10:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS initiates coverage on Insmed with a Buy rating and a price target of $46.
The initiation of coverage by UBS with a Buy rating and a significant price target suggests a positive outlook for Insmed's stock. This could lead to increased investor interest and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100